Afimoxifene
From Self-sufficiency
| Afimoxifene | |
|---|---|
| File:Afimoxifene.png | |
| (Z)-4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol | |
| Other names 4-hydroxytamoxifen | |
| style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers | |
| CAS number | 68392-35-8 |
| PubChem | 449459 |
| SMILES | Script error: No such module "collapsible list". |
| style="background: #F8EABA; text-align: center;" colspan="2" | Properties | |
| Molecular formula | C26H29NO2 |
| Molar mass | 387.51396 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
Afimoxifene[1] is a selective estrogen receptor modulator whose active ingredient is 4-hydroxytamoxifen which is identical to the active metabolite of tamoxifen.[2] Afimoxifene is a transdermal gel formulation and is being developed by Ascend Therapeutics, Inc. under the trademark TamoGel.[1] Afimoxifene has completed a phase II clinical trial for the treatment of cyclical mastalgia.[3]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />External links
 |
This pharmacology-related article is a stub. You can help ssf by expanding it. |
- ↑ 1.0 1.1 "Statement on a nonproprietary name adopted by the USAN council: Afimoxifene" (PDF). American Medical Association. Retrieved 2008-03-26.
- ↑ Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004). "Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6". J Pharmacol Exp Ther. 310 (3): 1062–75. doi:10.1124/jpet.104.065607. PMID 15159443.
- ↑ Mansel R, Goyal A, Nestour EL, Masini-Etévé V, O'Connell K (2007). "A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women". Breast Cancer Res. Treat. 106 (3): 389–97. doi:10.1007/s10549-007-9507-x. PMID 17351746.
